Efficacy and safety of tofacitinib in treating unstable refractory vitiligo in a tertiary care center: A prospective study
Dr B JAYA SAI
, Dr M MADHAVI LATHA , Dr T PRAVEENA
melanocytes, vitiligo, tofacitinib
Abstract—BACKGROUND: Vitiligo is a common acquired skin disorder which results from the loss of melanocytes. Standard treatment for vitiligo often has unsatisfactory outcomes. With a new understanding of pathogenesis novel drugs have been introduced which have shown to be effective. Tofacitinib, a Janus kinase 1&3 inhibitor has shown promising results. AIMS AND OBJECTIVES: To study the efficacy and safety of Tofacitinib in treating unstable refractory vitiligo. MATERIALS AND METHODS: Total of 25 vitiligo patients were included in this study who attended DVL OPD, and were given Tofacitinib 5mg OD for 12 weeks. A detailed clinical history, baseline investigations like CBP, LFT, RFT, Thyroid profile, lipid profile , and clinical photographs were taken at the first visit which were repeated at 6 & 12 weeks. Improvement in depigmentation was assessed using Vitiligo Area Scoring Index (VASI) and vitiligo activity was assessed using Vitiligo Disease Activity score (VIDA). RESULTS: Majority of patients had generalized vitiligo(18) , others had mucocal vitiligo(3), segmental vitiligo(2), acrofacial vitiligo (2) . On assessment with VASI score 60 % of patients showed improvement with reduction of 12 points, 25 % showed improvement with reduction of 6 points, very mild improvement was seen in 15 % patients with reduction of 0-2 points and 80 % of patients showed decreased disease activity measured by VIDA score. One patient showed adverse effects like altered lipid profile and other patient had recurrent fever and respiratory tract infections. LIMITATIONS: Small size of the Sample. CONCLUSION: Tofacitinib as JAK inhibitor monotherapy appeared to be effective and safe in treating unstable refractory vitiligo patients.
"Efficacy and safety of tofacitinib in treating unstable refractory vitiligo in a tertiary care center: A prospective study ", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.9, Issue 6, page no.1316 - 1322, June-2024, Available :https://ijsdr.org/papers/IJSDR2406152.pdf
Volume 9
Issue 6,
June-2024
Pages : 1316 - 1322
Paper Reg. ID: IJSDR_211906
Published Paper Id: IJSDR2406152
Downloads: 000347094
Research Area: Medical Science
Country: NANDYAL , ANDHRA PRADESH, INDIA
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
